secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001558370-25-009739
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris ATI-2138 Phase 2a AD trial meets primary and key secondary endpoints; 60.5% mean EASI improvement at week 12
--------------------------------------------------------------------------------

- 14 patients enrolled; 10 per protocol; no SAEs or discontinuations; well tolerated with mild, transient TRAEs.
- Mean EASI improvement 60.5% (77.1% excluding one outlier); 62.5% achieved ≥4-point itch reduction at week 12.
- PD data show near-complete ITK target occupancy and downregulation of Th2, Th1/Th17, and fibrosis markers.
- Company plans to further develop ATI-2138 in alopecia areata and explore other indications.
- Preclinical work ongoing for next-gen ITK inhibitors; new INDs expected starting 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/0001558370-25-009739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/acrs-20250729x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-009739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer